+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Spinal Muscular Atrophy Market [(By Drugs - Spinraza, Zolgensma, Risdiplam & Reldesemtiv; By Region - North America (The US), Europe & Asia Pacific)] Market Outlook 2027

  • ID: 5088976
  • Report
  • June 2020
  • Region: Global, North America, United States, Europe, Asia Pacific
  • 97 Pages
  • Rockville Research
1 of 4
The Global Spinal Muscular Atrophy Market is Estimated to be Valued at US$ 2.8 Billion in the Year 2027, Growing at a CAGR of 12.5%

FEATURED COMPANIES

  • Biogen Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • MORE

Industry Insights

According to a new report, the Global Spinal Muscular Atrophy (SMA) market is estimated to be valued at US$ 2.8 billion in the year 2027, growing at a CAGR of 12.5% in the period 2020 to 2027. Growth of the market is driven by rising incidences of SMA, technological advancements, government impetus, growing consumer awareness and surge in R&D activities.

SMA is a rare genetic disorder that affects the part of the central nervous system which controls voluntary muscle movements. It is one of the most common debilitating genetic disorders and a leading genetic cause of death among infants. It affects approximately one in 10,000 live births globally.

FDA Approval of Zolgensma, first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), has become a milestone in the treatment of patients with SMA. It has emerged as a potential game-changer for SMA treatment. Furthermore, there are various other emerging ongoing clinical trials currently in the process of evaluating its efficacy of either SMN-dependent or SMN-independent approaches.

Report Scope

This report “Global Spinal Muscular Atrophy Market [(By Drugs - Spinraza, Zolgensma, Risdiplam & Reldesemtiv; By Region - North America (The US), Europe & Asia Pacific)] Market Outlook 2027” provides detailed analysis of the global SMA market from qualitative and quantitative outlooks during the forecast period across various therapeutic segments. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

Parameter Description

  • Base Year: 2016
  • Forecast Period: 2020 - 2027
  • Market Sizing: Revenue in US$ Millions and Numbers in Millions & CAGR for the period 2016 to 2027
  • Vendor Scope: Biogen Inc., Cytokinetics Inc., AveXis Inc., F. Hoffman - La Roche & Ionis Pharmaceuticals Inc.
  • Report Coverage: Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles

Segments Covered

The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, The publisher has segmented global Spinal Muscular Atrophy market report on the basis of therapeutics and region:

Therapeutics, Revenue (2017-2027E, US$ Millions)

  • Spinraza
  • Zolgensma
  • Risdiplam
  • Reldesemtiv

Regional Outlook, Revenue (2016 - 2027E, US$ Millions)

  • North America
  • Europe
  • Asia Pacific

Country Outlook, Revenue (2016 - 2027E, US$ Millions)

  • The US

Vendors Outlook, Revenue (2013 - 2023E, US$ Billions)

  • Biogen Inc.
  • Cytokinetics Inc.
  • AveXis Inc.
  • F. Hoffman -La Roche
  • Ionis Pharmaceuticals Inc.

Target Audience

  • SMA Drug Manufacturers
  • Chemical Suppliers
  • End Users
  • Research Professionals
  • Healthcare Consultancies
  • Regulatory Bodies

Key questions answered in the report

  • The historical market size of the SMA market from 2016 to 2019 in US$ Millions and market volume in Millions.
  • Projected market growth in the forecasted period 2020 to 2025 with estimated revenue for each year in US$ Millions.
  • Revenue forecasts of major drugs in the period 2020 to 2027 in US$ Millions.
  • Regional and country analysis of SMA market is provided for the period 2016 to 2027 in US$ Millions.
  • Market drivers, restraints and industry trends that have an impact on revenue.
  • Profiling of major companies with detailed analysis of drugs approved and in the pipeline.

Customization

The publisher provides customization of the study in order to provide specific information as sought by the client.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • MORE

1. Executive Summary

2. Research Methodology

3. Spinal Muscular Atrophy
3.1 Overview
3.1.1 Causes
3.1.2 Symptoms of SMA
3.1.3 Types of Diseases
3.2 Diagnosis & Treatment
3.2.1 Diagnosis
3.2.2 Treatment
3.2.2.1 Gene Therapy
3.2.2.2 Medications
3.2.2.3 Existing Treatment Paradigm

4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.1.1 Market Sizing by Value (Actual & Forecasted)
4.1.2 Market Sizing by Volume (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Disease Type
4.2.2 Market Share by Route of Administration
4.2.3 Market Share by Region
4.2.4 Market Share by Patient Age-Group

5. Market Segmentation by Drugs
5.1 Spinraza
5.1.1 Overview
5.1.2 Market Sizing (Actual & Forecasted)
5.2 Zolgensma (AVXS - 101)
5.2.1 Overview
5.2.2 Market Sizing (Actual & Forecasted)
5.2.3 Market Share by Disease Type
5.2.4 Market Share by Region
5.3 Risdiplam
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
5.3.3 Market Share by Disease Type
5.3.4 Market Share by Region
5.4 Reldesemtiv
5.4.1 Overview
5.4.2 Market Sizing (Actual & Forecasted)

6. Regional Analysis
6.1 North America - The US
6.1.1 Market Sizing by Value (Actual & Forecasted)
6.1.2 Market Sizing by Volume (Actual & Forecasted)
6.1.3 Market Share by Treatment
6.1.4 Market Share by Prevalence of Disease
6.2 Europe
6.2.1 Market Sizing by Value (Actual & Forecasted)
6.2.2 Market Sizing by Volume (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing by Value (Actual & Forecasted)

7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 FDA Approval of Innovative Gene Therapy
7.1.2 Mergers & Acquisitions
7.1.3 Advent of Oral mRNA Splicer for Treatment
7.1.4 Use of MRI as a Diagnostic Technique
7.2 Growth Drivers
7.2.1 Rising Incidences of SMA
7.2.2 Technological Advancements
7.2.3 Government Impetus
7.2.4 Growing Consumer Awareness
7.2.5 Surge in R&D Activities
7.3 Challenges
7.3.1 High Cost of Therapy
7.3.2 Low Adoption of Treatment
7.3.3 Unfavorable Reimbursement Policies

8. Competitive Landscape
8.1 Financial Analysis
8.2 Products Landscape

9. Company Profiles
9.1 Biogen Inc.
9.2 Cytokinetics, Inc.
9.3 AveXis, Inc. (Novartis AG)
9.4 F. Hoffmann-La Roche AG
9.5 Ionis Pharmaceuticals, Inc.

List of Figures and Tables
Figure 1: Research Methodology
Figure 2: Spinal Muscular Atrophy (SMA) Disease Mechanism
Figure 3: Diagrammatic Representation of Causes of SMA
Table 1: Characteristics of SMA by Subtypes
Table 2: Severity of Spinal Muscular Atrophy by Disease Type
Figure 4: Diagrammatic Representation of SMN1 Gene Therapy
Figure 5: Therapeutic Intervention in Spinal Muscular Atrophy (SMA)
Figure 6: Global Spinal Muscular Atrophy Market Size by Value, 2016-27E (US$ Millions)
Figure 7: Global Spinal Muscular Atrophy Market Size by Volume, 2016-27E (Millions)
Figure 8: Global Spinal Muscular Atrophy Incidence by Disease Type (2019)
Table 3: Incidence of SMA by Sub-type
Figure 9: Global Spinal Muscular Atrophy Market Share by Route of Administration (2019)
Figure 10: Global Spinal Muscular Atrophy Market Share by Region (2019)
Figure 11: Global Spinal Muscular Atrophy Market Share by Patient Age-Group (2019)
Figure 12: Global SMA Drug - Spinraza Net Sales, FY2017-FY2027E (US$ Billions)
Table 4: Zolgensma (AVXS-101) Potential Milestones & Pipeline
Figure 13: Global SMA Drug - Zolgensma (AVXS-101) Net Sales, FY2018E-FY2027E (US$ Millions)
Figure 14: Global SMA Drug - Zolgensma (AVXS-101) Market Share by Disease Type (2020E)
Figure 15: Global SMA Drug - Zolgensma (AVXS-101) Market Share by Region (2020E)
Figure 16: Global SMA Drug - Risdiplam Net Sales Forecast, FY2020E-FY2027E (US$ Millions)
Figure 17: Global SMA Drug - Risdiplam Market Share by Disease Type (2020E)
Figure 18: Global SMA Drug - Risdiplam Market Share by Region (2020E)
Figure 19: Global SMA Drug - Reldesemtiv Net Sales Forecast, FY2021E-FY2025E (US$ Billions)
Figure 20: The US Spinal Muscular Atrophy (SMA) Market Size by Value, 2016-27E (US$ Millions)
Table 5: SMA Prevalence in the US
Figure 21: The US Spinal Muscular Atrophy (SMA) Market Share by Treatment, 2019 & 2027E
Figure 22: The US Spinal Muscular Atrophy (SMA) Prevalence by Type of Disease (2019)
Figure 23: Europe Spinal Muscular Atrophy (SMA) Market Size by Value, 2016-27E (US$ Millions)
Table 6: SMA Prevalence in Europe
Figure 24: Asia Pacific Spinal Muscular Atrophy (SMA) Market Size by Value, 2018-27E (US$ Millions)
Table 6: Mergers & Acquisitions in SMA Market
Figure 25: Spinal Muscular Atrophy (SMA) Incidences by Nations (2019)
Table 7: Leading SMA Drug Manufacturers Revenue Forecast, FY2017-FY2022E (US$ Billion)
Table 8: Global SMA Drug Manufacturers Financial Analysis (FY2019)
Table 9: Spinal Muscular Atrophy (SMA) Drugs by Clinical Safety Profile
Table 10: Spinal Muscular Atrophy (SMA) Drugs Patient Population and Developmental Status
Table 11: Comparative Analysis of Spinal Muscular Atrophy (SMA) Drugs
Table 12: Spinal Muscular Atrophy (SMA) Drugs Competitive Portfolio
Table 13: Spinal Muscular Atrophy (SMA) Drugs Clinical Trials Pipeline
Table 14: Assessment of Drug (AVXS-101, Risdiplam & Spinraza) Efficacy on SMA Type 1
Table 15: Biogen Inc. Drug - Spinraza Sales, 2016-27E (US$ Millions)
Table 16: Biogen Inc. SMA Drugs Clinical Pipeline
Figure 26: Biogen Inc. Revenue by Business Segment (FY2019)
Figure 27: Biogen Inc. Net Sales, FY2013-FY2019 (US$ Billions)
Table 17: Cytokinetics, Inc. Drug - Reldesemtiv Clinical Trial
Figure 28: Cytokinetics Inc. Revenue by Business Segment (FY2019)
Figure 29: Cytokinetics Inc. Net Sales, FY2013-FY2019 (US$ Billions)
Table 18: Avexis Inc. SMA Existing Drugs
Table 19: Avexis Inc. SMA Drugs Pipeline
Table 20: AVXS-101 Sales Potential, 2019-23E (US$ Millions)
Figure 30: Novartis AG Revenue by Business Segment (FY2019)
Figure 31: Avexis Inc. Net Sales, FY2013-FY2019 (US$ Billions)
Figure 32: F. Hoffmann-La Roche AG Revenue by Business Segment (FY2019)
Table 21: Risdiplam Sales Potential, 2019-23E (US$ Millions)
Figure 33: F. Hoffmann-La Roche AG Net Sales, FY2013-FY2019 (US$ Billions)
Figure 34: Ionis Pharmaceuticals, Inc. Revenue by Business Segment (FY2019)
Figure 35: Ionis Pharmaceuticals, Inc. Net Sales, FY2013-FY2019 (US$ Billions)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • MORE

Spinal Muscular Atrophy (SMA) is a congenital neuromuscular disorder that is often characterized by loss of specialized nerve cells, called motor neurons, in the spinal cord and brainstem. It is a rare genetic disorder that affects the part of the central nervous system which controls voluntary muscle movements. It is the most common cause of infant death resulting from a genetic defect. It is caused by low levels of the survival motor neuron protein (SMN) resulting from SMN1 gene mutations or deletions. This progressive hereditary neuromuscular disorder varies in severity depending on disease subtype, resulting in respiratory and mobility impairment. It is categorized into four subtypes on the basis of severity - Type I or Infantile, Type II or Intermediate, Type III or Juvenile and Type IV or Adult. SMA type 1 is the most severe form with the highest mortality rate.

Ongoing research on understanding SMA pathophysiology has led to the emergence of multiple therapeutic approaches for the treatment of patients with SMA. There are various SMA therapies currently in clinical trial phase which is expected to get approval soon. Growth of global SMA is driven by rising incidences of spinal muscular atrophy, technological advancement in the industry, government impetus, growing consumer awareness and surge in R&D activities. However, the market faces several challenges due to the high cost of treatment and low adoption of treatment and unfavourable reimbursement policies.

The report “Global Spinal Muscular Atrophy Market [(By Drugs - Spinraza, Zolgensma, Risdiplam & Reldesemtiv; By Region - North America (The US), Europe & Asia Pacific)] Market Outlook 2027” provides in-depth analysis of the current scenario, the detailed market outlook of the global spinal muscular atrophy market with coverage on major therapeutics such as Spinraza, Zolgensma, Risdiplam & Reldesemtiv. Future forecasts of spinal muscular atrophy market overall and across various sub-segments till 2027 is provided in the report. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.

Major industry players operating in the global spinal muscular atrophy market include Biogen Inc., Cytokinetics Inc., AveXis Inc., F. Hoffman - La Roche & Ionis Pharmaceuticals Inc., among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles the performance comparison of the aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in the global spinal muscular atrophy market.

Note: Product cover images may vary from those shown
5 of 4
  • AveXis, Inc. (Novartis AG)
  • Biogen Inc.
  • Cytokinetics, Inc.
  • F. Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll